Easterly Investment Partners LLC Has $558,000 Position in Pfizer Inc. (NYSE:PFE)

Easterly Investment Partners LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 70.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,113 shares of the biopharmaceutical company’s stock after selling 47,243 shares during the quarter. Easterly Investment Partners LLC’s holdings in Pfizer were worth $558,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in PFE. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares in the last quarter. Creekmur Asset Management LLC acquired a new position in Pfizer during the fourth quarter worth $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. VisionPoint Advisory Group LLC increased its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer during the 4th quarter worth about $36,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday. Finally, Morgan Stanley lifted their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Trading Up 2.3 %

Shares of PFE stock traded up $0.65 during trading hours on Wednesday, reaching $28.37. The company had a trading volume of 15,098,941 shares, compared to its average volume of 39,925,516. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.80. The company has a 50 day moving average of $28.18 and a 200 day moving average of $27.71. The firm has a market cap of $160.76 billion, a price-to-earnings ratio of -469.59, a P/E/G ratio of 1.10 and a beta of 0.69.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.23 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.92%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.